New award recognises industry's role in clinical trials

In recognition of the important role that industry plays in Australian clinical trials, a new Australian Clinical trials Alliance (ACTA) Industry Partnership Award has been launched.

At a time when the spotlight is firmly on clinical trials across the globe, this is an opportunity to tell the success stories of the ground-breaking work happening in the Australian clinical trials sector.

Open to Members and non-members, the Industry Partnership Award will celebrate a significant collaboration between an industry company and a team of academic investigators uniting to conduct a high-impact clinical trial.

To coincide with International Clinical Trials Day, the winner will be publicly announced at ACTA's National Tribute and Awards Ceremony, which will be held in Sydney on 20 May 2022.

The annual awards honour Australians advancing our health system by designing, conducting, or participating in ground-breaking clinical trials and promote the importance of clinical trials and the expertise and complexity of the work involving trial teams, industry partners and consumers.

In 2022, there nominations are being accepted for four award categories:

· ACTA Industry Partnership Award

· ACTA Trial of the Year Award

· ACTA STInG Excellence in Trial Statistics Award

· ACTA Consumer Involvement Award

Assessment of the Industry Partnership Award applications will be around the nature of the partnership; however, award judges will also be asked to confirm that the research undertaken in the trial in question was outstanding quality.

AusBiotech encourages you to learn more about the Awards and to make your nomination by midnight, Sunday 6 March 2022.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.